Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) EVP Eric Swayze sold 5,631 shares of the firm’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $39.74, for a total value of $223,775.94. Following the transaction, the executive vice president now directly owns 30,041 shares of the company’s stock, valued at approximately $1,193,829.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Ionis Pharmaceuticals Stock Up 0.4 %
Shares of Ionis Pharmaceuticals stock opened at $40.76 on Friday. The stock has a 50-day moving average price of $39.53 and a 200 day moving average price of $41.80. The company has a market cap of $5.79 billion, a P/E ratio of -339.64 and a beta of 0.54. The company has a current ratio of 7.59, a quick ratio of 7.52 and a debt-to-equity ratio of 2.10. Ionis Pharmaceuticals, Inc. has a 1 year low of $28.25 and a 1 year high of $48.82.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.41. The firm had revenue of $160.00 million during the quarter, compared to the consensus estimate of $149.48 million. Ionis Pharmaceuticals had a return on equity of 1.18% and a net margin of 0.91%. As a group, analysts expect that Ionis Pharmaceuticals, Inc. will post -2.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Morgan Stanley cut Ionis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $56.00 to $40.00 in a research note on Wednesday, December 21st. Barclays raised their target price on Ionis Pharmaceuticals to $44.00 in a research note on Tuesday, November 15th. SVB Leerink decreased their target price on Ionis Pharmaceuticals from $30.00 to $26.00 and set a “market perform” rating for the company in a research note on Thursday, November 10th. Citigroup increased their price target on Ionis Pharmaceuticals from $28.00 to $31.00 and gave the company a “sell” rating in a research report on Thursday, November 10th. Finally, Piper Sandler increased their price target on Ionis Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $43.22.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases.
- Get a free copy of the StockNews.com research report on Ionis Pharmaceuticals (IONS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.